Related Experiment Video
Updated: Jul 11, 2026
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
Fermented Wheat Germ Protein with Histone Deacetylase Inhibitor AR42 Demonstrates Enhanced Cytotoxicity against
Joshua F Meckler1, Daniel J Levis1, Yanguo Kong1
1Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA 95817, USA.
Abstract:
Current treatments for lymphoma are plagued by substantial toxicity and the inability to overcome drug resistance, leading to eventual relapse and rationalizing the development of novel, less toxic therapeutics and drug combinations. Histone deacetylase inhibitors (HDACis) are a broad class of epigenetic modulators that have been studied in multiple tumor types, including lymphoma. Currently, HDACis are FDA-approved for treating relapsed T-cell lymphomas and multiple myeloma, with ongoing trials in other lymphomas and solid tumors. As single agents, HDACis frequently elicit toxic side effects and have limited efficacy; therefore, many current treatment strategies focus on combinations to boost efficacy while attempting to minimize toxicity. Fermented wheat germ extract (FWGE) is a complementary agent that has shown efficacy in several malignancies, including lymphoma. Here, we utilize a more potent FWGE derivative, known as fermented wheat germ protein (FWGP), in combination with the HDACi AR42, to assess for enhanced activity. We report increased in vitro killing, cell cycle arrest, and in vivo efficacy for this combination compared to each agent alone with minimal toxicity, suggesting a potentially new, minimally toxic treatment modality for lymphoma.
Insights
Fermented wheat germ protein (FWGP) combined with the histone deacetylase inhibitor (HDACi) AR42 shows enhanced efficacy against lymphoma. This novel combination demonstrates increased cancer cell killing and reduced toxicity, offering a promising new treatment approach.
Area of Science:
- Oncology
- Epigenetics
- Pharmacology
Background:
- Current lymphoma treatments face challenges with toxicity and drug resistance, leading to relapse.
- Histone deacetylase inhibitors (HDACis) are epigenetic modulators with approved uses in certain lymphomas and multiple myeloma.
- Single-agent HDACi therapy often results in significant toxicity and limited effectiveness, driving the need for combination strategies.
Purpose of the Study:
- To evaluate the efficacy of a combination therapy using fermented wheat germ protein (FWGP) and the HDACi AR42 in lymphoma.
- To determine if this combination enhances anti-lymphoma activity compared to individual agents.
- To assess the toxicity profile of the FWGP and AR42 combination.
Main Methods:
- In vitro studies assessing cancer cell killing and cell cycle arrest.
- In vivo efficacy studies in animal models of lymphoma.
- Comparative analysis of the combination therapy against single-agent treatments.
Main Results:
- The combination of FWGP and AR42 demonstrated significantly increased in vitro cancer cell killing.
- The combination induced cell cycle arrest in lymphoma cells more effectively than individual agents.
- In vivo studies showed enhanced anti-lymphoma efficacy with the combination therapy.
- The combined treatment exhibited minimal toxicity compared to single-agent therapies.
Conclusions:
- Fermented wheat germ protein (FWGP) in combination with AR42 represents a potentially novel and minimally toxic treatment modality for lymphoma.
- This combination therapy shows promise for overcoming limitations of current lymphoma treatments, including drug resistance and toxicity.
- Further investigation into this combination therapy is warranted for clinical application in lymphoma patients.
